Financial Results for the quarter ended June 30, 2026
RESULTS
◆ Monitor Closely
LOW RISK
📅 Filed on BSE: 31 Jul 2026, 07:22 PM IST · BSE ID: a51f2fbd-0cb3-445a-8989-e3af62620836
View Original BSE Filing (PDF)
💡
In Simple Terms
Aarti Drugs announced its financial results for April to June 2026, showing its profits and sales figures.
🤖 AI Summary
- Aarti Drugs reported Q1 FY27 standalone net profit of Rs. 5,085 lakhs for the quarter ended June 30, 2026.
- Standalone revenue from operations was Rs. 62,745 lakhs for Q1 FY27.
- Consolidated net profit reached Rs. 5,013 lakhs for the quarter ended June 30, 2026.
- Consolidated revenue from operations stood at Rs. 70,278 lakhs for Q1 FY27.
- An exceptional item of Rs. 2.09 Cr. was recorded for the write-off of Capital Work-in-Progress (CWIP).
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q1 FY27)
Rs. 62,745 lakhs
20.44
Standalone Profit / (Loss) for the Year (Q1 FY27)
Rs. 5,085 lakhs
4.54
Consolidated Revenue from operations (Q1 FY27)
Rs. 70,278 lakhs
19.01
Consolidated Profit / (Loss) for the Year (Q1 FY27)
Rs. 5,013 lakhs
-7.01
Exceptional item (CWIP write-off)
Rs. 2.09 Cr.
🏢 How This Affects the Company
The financial results provide a performance update for the pharmaceuticals segment, which is the company's sole business segment.
The company recorded standalone net profit of Rs. 5,085 lakhs and consolidated net profit of Rs. 5,013 lakhs, influencing overall earnings and profitability metrics.
The write-off of Capital Work-in-Progress (CWIP) of Rs. 2.09 Cr. indicates an adjustment related to administrative building assets, which is part of routine expansion plans.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the disclosed financial performance, as it reflects the company's profitability and operational efficiency for the quarter.
🔍
Management Signal
The approval of audited results indicates management's commitment to financial transparency and fulfilling regulatory disclosure requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check for revenue and profit trends.
Updates on new capacity additions or business expansion initiatives.
Disclosure of any new orders or strategic partnerships.
LOW RISK
The filing reports routine quarterly financial results with an unmodified audit opinion.
💡 Investor Takeaway
Aarti Drugs reported Q1 FY27 standalone net profit of Rs. 5,085 lakhs and consolidated net profit of Rs. 5,013 lakhs. Standalone revenue was Rs. 62,745 lakhs and consolidated revenue was Rs. 70,278 lakhs. An exceptional item of Rs. 2.09 Cr. for CWIP write-off was recorded.
⚖️ Strengths & Concerns
✅ Positives
- Aarti Drugs reported a Q1 FY27 standalone net profit of Rs. 5,085 lakhs, compared to Rs. 4,496 lakhs in Q4 FY26.
- Consolidated revenue from operations for Q1 FY27 was Rs. 70,278 lakhs, indicating business activity.
⚠️ Concerns
- Consolidated net profit for Q1 FY27 was Rs. 5,013 lakhs, a decrease from Rs. 5,526 lakhs in Q4 FY26.
- Consolidated revenue from operations decreased to Rs. 70,278 lakhs in Q1 FY27 from Rs. 72,030 lakhs in Q4 FY26.
📅 Company Track Record
Aarti Drugs reported FY26 Consolidated Profit of Rs. 19,494 lakhs, up 16.09% YoY in its May 15, 2026 filing. The company held a board meeting on July 31, 2026, to approve the Q1 FY27 financial results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Aarti Drugs' consolidated net profit for Q1 FY27?
Aarti Drugs reported a consolidated net profit of Rs. 5,013 lakhs for the quarter ended June 30, 2026.
What was Aarti Drugs' standalone revenue from operations in Q1 FY27?
The standalone revenue from operations for Aarti Drugs was Rs. 62,745 lakhs for the quarter ended June 30, 2026.
Was there any exceptional item reported in Aarti Drugs' Q1 FY27 results?
Yes, an exceptional item representing a write-off of Capital Work-in-Progress (CWIP) of Rs. 2.09 Cr. was reported in Q1 FY27.
What was Aarti Drugs' consolidated revenue from operations for Q1 FY27?
Aarti Drugs' consolidated revenue from operations was Rs. 70,278 lakhs for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.